Overview of the 2022 WHO classification of thyroid neoplasms

ZW Baloch, SL Asa, JA Barletta, RA Ghossein… - Endocrine …, 2022 - Springer
This review summarizes the changes in the 5th edition of the WHO Classification of
Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new …

Biologic and clinical perspectives on thyroid cancer

JA Fagin, SA Wells Jr - New England Journal of Medicine, 2016 - Mass Medical Soc
Biologic and Clinical Perspectives on Thyroid Cancer | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …

Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers

N Pozdeyev, LM Gay, ES Sokol, R Hartmaier… - Clinical Cancer …, 2018 - AACR
Purpose: To define the genetic landscape of advanced differentiated and anaplastic thyroid
cancer (ATC) and identify genetic alterations of potential diagnostic, prognostic, and …

Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond

ME Cabanillas, M Ryder, C Jimenez - Endocrine reviews, 2019 - academic.oup.com
The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

I Landa, T Ibrahimpasic, L Boucai… - The Journal of …, 2016 - Am Soc Clin Investig
BACKGROUND. Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer
(ATC) are rare and frequently lethal tumors that so far have not been subjected to …

[HTML][HTML] Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation …

DT Cheng, TN Mitchell, A Zehir, RH Shah… - The Journal of molecular …, 2015 - Elsevier
The identification of specific genetic alterations as key oncogenic drivers and the
development of targeted therapies are together transforming clinical oncology and creating …

2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association …

BR Haugen, EK Alexander, KC Bible, GM Doherty… - Thyroid, 2016 - liebertpub.com
Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Pathogenesis of cancers derived from thyroid follicular cells

JA Fagin, GP Krishnamoorthy, I Landa - Nature reviews Cancer, 2023 - nature.com
The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence

M Xing, R Liu, X Liu, AK Murugan, G Zhu… - Journal of clinical …, 2014 - ascopubs.org
Purpose To investigate the prognostic value of the BRAF V600E mutation and the recently
identified TERT promoter mutation chr5: 1,295,228 C> T (C228T), individually and in their …

Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes

I Ganly, V Makarov, S Deraje, YY Dong, E Reznik… - Cancer cell, 2018 - cell.com
The molecular foundations of Hürthle cell carcinoma (HCC) are poorly understood. Here we
describe a comprehensive genomic characterization of 56 primary HCC tumors that span …